Literature DB >> 30776001

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease.

Xin Wang1, Helena R Zimmermann1, Tao Ma1,2,3.   

Abstract

Currently there is no cure or effective disease-modifying therapy for Alzheimer's disease (AD), the most common form of dementia that is becoming a global threat to public health. It is important to develop novel therapeutic strategies targeting AD pathophysiology particularly synaptic failure and cognitive impairments. Recent studies revealed several molecular signaling pathways potentially linked to brain pathology and synaptic failure in AD, including AMP-activated protein kinase (AMPK), a master kinase that plays a central role in the maintenance of cellular energy homeostasis. Particularly, hyperactive AMPK via phosphorylation has been linked to AD-associated synaptic plasticity impairments, indicating suppression of AMPK activity might be beneficial for cognitive deficiency in AD. In this review, we will discuss how targeting dysregulation of AMPK signaling could be a feasible therapeutic approach for AD.

Entities:  

Keywords:  AMPK; Alzheimer’s disease; protein synthesis; signaling transduction; synaptic plasticity

Mesh：

Substances：

Year:  2019        PMID： 30776001      PMCID： PMC6446925          DOI： 10.3233/JAD-181043

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN： 1387-2877            Impact factor:   4.472


  53 in total

1.  Sustained translational repression by eIF2α-P mediates prion neurodegeneration.

Authors:  Julie A Moreno; Helois Radford; Diego Peretti; Joern R Steinert; Nicholas Verity; Maria Guerra Martin; Mark Halliday; Jason Morgan; David Dinsdale; Catherine A Ortori; David A Barrett; Pavel Tsaytler; Anne Bertolotti; Anne E Willis; Martin Bushell; Giovanna R Mallucci
Journal:  Nature       Date:  2012-05-06       Impact factor: 49.962

Review 2.  Biochemical mechanisms for translational regulation in synaptic plasticity.

Authors:  Eric Klann; Thomas E Dever
Journal:  Nat Rev Neurosci       Date:  2004-12       Impact factor: 34.870

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

4.  Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Authors:  Tao Ma; Yiran Chen; Valerie Vingtdeux; Haitian Zhao; Benoit Viollet; Philippe Marambaud; Eric Klann
Journal:  J Neurosci       Date:  2014-09-03       Impact factor: 6.167

5.  Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system.

Authors:  A M Turnley; D Stapleton; R J Mann; L A Witters; B E Kemp; P F Bartlett
Journal:  J Neurochem       Date:  1999-04       Impact factor: 5.372

6.  Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3.

Authors:  Tao Ma; Nikos Tzavaras; Panayiotis Tsokas; Emmanuel M Landau; Robert D Blitzer
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

7.  Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes.

Authors:  Ying Liu; Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  J Pathol       Date:  2011-05-19       Impact factor: 7.996

8.  Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.

Authors:  Annett Hahn-Windgassen; Veronique Nogueira; Chia-Chen Chen; Jennifer E Skeen; Nahum Sonenberg; Nissim Hay
Journal:  J Biol Chem       Date:  2005-07-15       Impact factor: 5.157

9.  Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.

Authors:  Dan Liu; Hui Tang; Xin-Yan Li; Man-Fei Deng; Na Wei; Xiong Wang; Ya-Fan Zhou; Ding-Qi Wang; Peng Fu; Jian-Zhi Wang; Sébastien S Hébert; Jian-Guo Chen; Youming Lu; Ling-Qiang Zhu
Journal:  Mol Ther       Date:  2017-02-13       Impact factor: 11.454

10.  Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons.

Authors:  Gisele S Seixas da Silva; Helen M Melo; Mychael V Lourenco; Natalia M Lyra E Silva; Marcelo B de Carvalho; Soniza V Alves-Leon; Jorge M de Souza; William L Klein; Wagner S da-Silva; Sergio T Ferreira; Fernanda G De Felice
Journal:  J Biol Chem       Date:  2017-03-16       Impact factor: 5.157
View more
  19 in total

Review 1.  Research Progress on Alzheimer's Disease and Resveratrol.

Authors:  Yan Yan; Huihuang Yang; Yuxun Xie; Yuanlin Ding; Danli Kong; Haibing Yu
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

2.  Decreased Levels of Blood AMPKα1 but not AMPKα2 Isoform in Patients with Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study.

Authors:  Xin Wang; Helena R Zimmermann; Samuel N Lockhart; Suzanne Craft; Tao Ma
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

3.  Antagonists targeting eEF2 kinase rescue multiple aspects of pathophysiology in Alzheimer's disease model mice.

Authors:  Nicole P Kasica; Xueyan Zhou; Qian Yang; Xin Wang; Wenzhong Yang; Helena R Zimmermann; Caroline E Holland; Elizabeth Koscielniak; Hanzhi Wu; Anderson O Cox; Jingyun Lee; Alexey G Ryazanov; Cristina M Furdui; Tao Ma
Journal:  J Neurochem       Date:  2022-01-04       Impact factor: 5.372

4.  Characterization of Early Alzheimer's Disease-Like Pathological Alterations in Non-Human Primates with Aging: A Pilot Study.

Authors:  Hannah M Jester; Saahj P Gosrani; Huiping Ding; Xueyan Zhou; Mei-Chuan Ko; Tao Ma
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 5.  Roles of eukaryotic elongation factor 2 kinase (eEF2K) in neuronal plasticity, cognition, and Alzheimer disease.

Authors:  Tao Ma
Journal:  J Neurochem       Date:  2021-11-19       Impact factor: 5.546

6.  Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.

Authors:  Helena R Zimmermann; Wenzhong Yang; Nicole P Kasica; Xueyan Zhou; Xin Wang; Brenna C Beckelman; Jingyun Lee; Cristina M Furdui; C Dirk Keene; Tao Ma
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

7.  Protein expression alteration in hippocampus upon genetic repression of AMPKα isoforms.

Authors:  Wenzhong Yang; Xueyan Zhou; Xin Wang; Jingyun Lee; Dan Wu; Peiqing Sun; Cristina M Furdui; Tao Ma
Journal:  Hippocampus       Date:  2021-01-25       Impact factor: 3.899

Review 8.  Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.

Authors:  Henry Querfurth; Han-Kyu Lee
Journal:  Mol Neurodegener       Date:  2021-07-02       Impact factor: 14.195

9.  Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer's disease.

Authors:  Xin Wang; Xueyan Zhou; Beth Uberseder; Jingyun Lee; Caitlin S Latimer; Cristina M Furdui; C Dirk Keene; Thomas J Montine; Thomas C Register; Suzanne Craft; Carol A Shively; Tao Ma
Journal:  Neurobiol Dis       Date:  2021-08-04       Impact factor: 7.046

Review 10.  Using the Oxytosis/Ferroptosis Pathway to Understand and Treat Age-Associated Neurodegenerative Diseases.

Authors:  Pamela Maher; Antonio Currais; David Schubert
Journal:  Cell Chem Biol       Date:  2020-11-10       Impact factor: 8.116
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.